Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday, February 27, 2019, after the close of the U.S. financial markets.
February 20, 2019
· 1 min read